Marina Biotech Announces a License Agreement to SMARTICLES and CRN platforms for Antisense DNA therapeutics

City of Industry, CA  July 19th, 2017 – Marina Biotech, Inc. (OTCQB: MRNA) a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension, and cancer, today announced that they have entered into a license agreement with Oncotelic, Inc. regarding the Company’s SMARTICLES™ platform for the delivery of Read More

Marina Biotech Announces the Appointment of Dr. Vuong Trieu as Executive Chairman

Company Also Announces Closing of a Note Financing Led by Dr. Trieu and Dr. Hwang, CSO.  CITY OF INDUSTRY, CA – Jul 5, 2017 – Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, announced today that Dr. Vuong Trieu, has been Read More

Marina Biotech Appoints Chief Commercial Officer to Lead Sales and Marketing of Prestalia®

Company to narrow its business focus to pain and hypertension; Company plans to sell or divest the oligonucleotide therapeutic assets. CITY OF INDUSTRY, CA – Jun 26, 2017 – Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for hypertension, arthritis, pain and oncology, announced today that Read More

Marina Biotech Acquires Prestalia®, a U.S. FDA Approved Drug for Patients Whose Blood Pressure Is Not Adequately Controlled by Monotherapy

City of Industry, CA – June 6, 2017 – Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, announced today that it has acquired Prestalia®, a treatment of hypertension, from Symplmed Pharmaceuticals Inc.. Hypertension remains a significant health issue Read More

Marina Biotech to Introduce Its Therapeutic Microbiome Programs Against Gastrointestinal Diseases

City of Industry, CA – May 30, 2017 – Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, today announced that it will be presenting two poster presentations at the 22nd Annual Meeting of the RNA Society being held Read More

Marina Biotech to Participate in Joseph Gunnar’s Pioneers 2017 Conference on May 2

City of Industry, CA – April 27, 2017 – Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, announced today that Joseph Ramelli, Chief Executive Officer, will present at Joseph Gunnar’s Pioneers 2017 Conference to be held at the Read More

Marina Biotech Provides Business Update

City of Industry, CA – April 5, 2017 – Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, provided today a corporate update to investors, following the filing of its 10-K for the year ended December 31, 2016 with Read More

Marina Biotech Signs Definitive Agreement with Windlas Healthcare to Manufacture IT-102 FDC Bi-Layer Tablet

City of Industry, CA – March 28th, 2017 – Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, today announced that it has signed a definitive agreement with Windlas Healthcare Limited for the manufacture of its IT-102 fixed-dose combination Read More

Marina Biotech to Present Data on Vascular Resistance and Cancer at the Endocrine Society Annual Meeting on April 1

City of Industry, CA – March 24th, 2017 – Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, today announced that a new poster1 on the use of antihypertensive for the treatment of cancer by targeting vascular resistance in Read More

Marina Biotech to Present A Late Breaking Poster on the Safety and Tolerability of CEQ508 for FAP at the Society of Toxicology 56th Annual Meeting on March 16

City of Industry, CA – March 13, 2017 – Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, today announced that a new poster1 on the safety and tolerability findings of the Company’s CEQ508, RNAi therapeutic in Familial Adenomatous Read More

Scroll Up